FDA Clearance Tracker · K180966
FilmArray Pneumonia Panel
Last checked: Nov 19, 2026Latest source record: Nov 9, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Nov 9, 2018
Substantially Equivalent
Time to decision
210 days
Received Apr 13, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K180966
- Device name
- FilmArray Pneumonia Panel
- Applicant
- Biofire Diagnostics, LLC
- Applicant location
- Salt Lake City, UT
- Received
- Apr 13, 2018
- Decided
- Nov 9, 2018
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Respiratory Panel (QDP)
- Device class
- Class II
- Regulation
- 21 CFR 866.3985
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code QDP (Respiratory Panel).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K180966
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Biofire Diagnostics, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262172 · Decided Nov 6, 2026 · 133 days after receipt
Device type: Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System (PCH) · Laboratory Medicine & Pathology
K262136 · Decided Oct 21, 2026 · 118 days after receipt
Device type: Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System (PQA) · Laboratory Medicine & Pathology
K243544 · Decided Aug 14, 2025 · 272 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.